

CITATION REPORT

List of articles citing

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

DOI: 10.1073/pnas.1410626111

Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11774-9.

Source: <https://exaly.com/paper-pdf/58334159/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
520	Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. 2015 , 17, 661-70		91
519	Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment. 2015 , 2, 4-15		
518	Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. 2015 , 128, 95-139		319
517	Immunotherapy of Melanoma. 2015 , 42, 22-9		12
516	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. 2015 , 28, 690-714		828
515	SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. 2015 , 3, 727-40		37
514	Decitabine: a promising epi-immunotherapeutic agent in solid tumors. 2015 , 11, 363-75		24
513	Immune checkpoint modulation: rational design of combination strategies. 2015 , 150, 23-32		62
512	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E966-72	11.5	295
511	Augmenting antitumor immune responses with epigenetic modifying agents. 2015 , 6, 29		119
510	Combination cancer immunotherapy and new immunomodulatory targets. 2015 , 14, 561-84		806
509	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. 2015 , 9, 6861-71		89
508	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. 2015 , 7, 641-52		38
507	Immune checkpoints and immunotherapy for colorectal cancer. 2015 , 3, 289-97		61
506	Relevance of tumor-infiltrating lymphocytes in breast cancer. 2015 , 13, 202		131
505	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. 2015 , 3, 1375-85		246
504	Targeting tumor-associated myeloid cells for cancer immunotherapy. 2015 , 4, e983961		7

503	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. 2015 , 21, 4040-7	75
502	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. 2016 , 4, 27	83
501	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. 2016 , 101, 794-802	62
500	The modulatory effects of mesenchymal stromal cells on the innate immune system. 2016 , 481-489	
499	A New VISTA on combination therapy for negative checkpoint regulator blockade. 2016 , 4, 86	27
498	Reprogramming the immunological microenvironment through radiation and targeting Axl. 2016 , 7, 13898	97
497	IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. 2016 , 197, 168-78	31
496	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. 2016 , 18, 632-44	124
495	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. 2016 , 8, 705-19	48
494	Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages. 2016 , 15, 1931-42	46
493	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. 2016 , 11, 313-41	12
492	CANCER. How neutrophils promote metastasis. 2016 , 352, 145-6	57
491	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. 2016 , 5, e1075114	31
490	ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. 2016 , 101, 968-75	40
489	EphA4-deleted microenvironment regulates cancer development and leukemoid reaction of the isografted 4T1 murine breast cancer via reduction of an IGF1 signal. 2016 , 5, 1214-27	15
488	Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). 2016 , 64, 74-82	20
487	The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. 2016 , 5, e1219008	39
486	Advances in immunotherapy for melanoma management. 2016 , 12, 2501-2511	13

485	HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. 2016 , 8, 1015-7	18
484	DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. 2016 , 65, 1061-73	28
483	Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1 β transcription factors. 2016 , 6, 33274	25
482	Interplay Between Inflammation and Epigenetic Changes in Cancer. 2016 , 144, 69-117	26
481	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. 2016 , 4, 895-902	93
480	Current condition and issues of animal evaluation models for cancer immunotherapy. 2016 , 148, 144-8	
479	Neutrophils in cancer: neutral no more. 2016 , 16, 431-46	829
478	Combinatorial approach to cancer immunotherapy: strength in numbers. 2016 , 100, 275-90	65
477	Novel Immunotherapeutic Approaches to the Treatment of Cancer. 2016 ,	1
476	Epigenetic therapy in gastrointestinal cancer: the right combination. 2016 , 9, 560-79	65
475	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. 2016 , 1-39	
474	The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer. 2016 , 12, 51-56	
473	The urgent need to recover MHC class I in cancers for effective immunotherapy. 2016 , 39, 44-51	329
472	Improving cancer immunotherapy with DNA methyltransferase inhibitors. 2016 , 65, 787-96	25
471	Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. 2016 , 5, e1151591	22
470	Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. 2016 , 130, 55-111	54
469	Myeloid-Derived Suppressor Cells Express Bruton β Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. 2016 , 76, 2125-36	121
468	-NT in cancer therapy. 2016 , 3, 144-152	49

467	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. 2016 , 28, 73-80	39
466	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. 2016 , 28, 54-63	31
465	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. 2016 , 22, 4119-32	183
464	Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. 2016 , 22, 8-10	45
463	Epigenetics in cancer stem cells. 2017 , 16, 29	195
462	Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. 2017 , 77, 817-822	88
461	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. 2017 , 24, R123-R144	45
460	Marked for death: targeting epigenetic changes in cancer. 2017 , 16, 241-263	172
459	Targeting the programmed death-1 pathway in lymphoid neoplasms. 2017 , 54, 99-109	18
458	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. 2017 , 9, 4	25
457	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. 2017 , 15, 5	23
456	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. 2017 , 60, 93-109	1
455	Immunoregulatory functions of VISTA. 2017 , 276, 66-79	104
454	Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. 2017 , 9,	292
453	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. 2017 , 7, 852-867	97
452	The mobility of mitochondria: Intercellular trafficking in health and disease. 2017 , 44 Suppl 1, 15-20	17
451	Epigenetics and immunotherapy: The current state of play. 2017 , 87, 227-239	128
450	Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. 2017 , 102, 727-740	64

449	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. 2017 , 99, 153-164	52
448	Therapeutic Options for Aggressive T-Cell Lymphomas. 2017 , 12, 269-281	3
447	DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. 2017 , 49, 1052-1060	157
446	Epigenetic modulation in cancer immunotherapy. 2017 , 35, 48-56	38
445	ZEB1-regulated inflammatory phenotype in breast cancer cells. 2017 , 11, 1241-1262	61
444	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. 2017 , 20, 81-86	31
443	Prospects for combining targeted and conventional cancer therapy with immunotherapy. 2017 , 17, 286-301	510
442	The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. 2017 , 113, 52-62	19
441	Entinostat: a promising treatment option for patients with advanced breast cancer. 2017 , 13, 1137-1148	54
440	Effective combinatorial immunotherapy for castration-resistant prostate cancer. 2017 , 543, 728-732	278
439	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. 2017 , 5, 29-41	190
438	Myeloid-Derived Suppressor Cells. 2017 , 5, 3-8	833
437	The biological and clinical significance of stromal-epithelial interactions in breast cancer. 2017 , 49, 133-140	19
436	Immunoplasticity in cutaneous melanoma: beyond pure morphology. 2017 , 470, 357-369	2
435	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). 2017 , 23, 7199-7208	57
434	A Blueprint to Advance Colorectal Cancer Immunotherapies. 2017 , 5, 942-949	40
433	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. 2017 , 3, 360-373	7
432	Neutrophils, a candidate biomarker and target for radiation therapy?. 2017 , 56, 1522-1530	31

431	No patient left behind: The promise of immune priming with epigenetic agents. 2017 , 6, e1315486	10
430	Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. 2017 , 102, 599-610	47
429	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. 2017 , 17S, S26-S30	5
428	Conditioning neoadjuvant therapies for improved immunotherapy of cancer. 2017 , 145, 12-17	7
427	Does CSF1R Blockade Turn into Friendly Fire?. 2017 , 32, 546-547	0
426	Immunological effects of hypomethylating agents. 2017 , 10, 745-752	31
425	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. 2017 , 23, 10-22	35
424	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. 2017 , 23, 5187-5201	211
423	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. 2017 , 9, 59	93
422	Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. 2017 , 241, 10-24	42
421	Neutrophils in cancer: prognostic role and therapeutic strategies. 2017 , 16, 137	169
420	Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. 2017 , 37, 267-278	21
419	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. 2017 , 8, 114156-114172	89
418	Clinical Applications of Histone Deacetylase Inhibitors. 2017 , 605-621	3
417	Epigenetic Strategies to Boost Cancer Immunotherapies. 2017 , 18,	22
416	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. 2017 , 8, 33159-33171	73
415	Targeting the epigenome in malignant pleural mesothelioma. 2017 , 6, 350-365	26
414	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. 2017 , 18,	46

4 ¹³	Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. 2017 , 8, 35326-35338	52
4 ¹²	Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. 2018 , 285, 717-733	34
4 ¹¹	Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review. 2018 , 97, e0434	2
4 ¹⁰	Implantable Synthetic Immune Niche for Spatiotemporal Modulation of Tumor-Derived Immunosuppression and Systemic Antitumor Immunity: Postoperative Immunotherapy. 2018 , 30, e1706719	63
4 ⁰⁹	Pembrolizumab and its role in relapsed/refractory classical Hodgkin lymphoma: evidence to date and clinical utility. 2018 , 9, 89-105	10
4 ⁰⁸	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. 2018 , 33, 581-598	261
4 ⁰⁷	Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. 2018 , 17, 811-822	35
4 ⁰⁶	Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. 2018 , 96, 888-897	33
4 ⁰⁵	Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model. 2018 , 99, 135-142	22
4 ⁰⁴	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. 2018 , 4, 1	52
4 ⁰³	Chemotherapy induces enrichment of CD47/CD73/PDL1 immune evasive triple-negative breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1239-E1248	11.5 141
4 ⁰²	Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells. 2018 , 17, 686-697	36
4 ⁰¹	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. 2018 , 23, 410-421	15
4 ⁰⁰	Mechanisms of resistance to immune checkpoint inhibitors. 2018 , 118, 9-16	576
399	Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. 2018 , 200, 422-431	266
398	A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status. 2018 , 39, 72-83	16
397	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. 2018 , 7, e1421891	40
396	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. 2018 , 11, 31	141

395	Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. 2018 , 6, 27	11
394	Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. 2018 , 10,	141
393	The role of epigenetic therapies in colorectal cancer. 2018 , 42, 530-547	36
392	Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. 2018 , 57, 4412-4428	81
391	Kleine Moleküle, ganz großniedermolekulare immunonkologische Kombinationstherapien. 2018 , 130, 4499-4516	0
390	Neutrophils, G-CSF and their contribution to breast cancer metastasis. 2018 , 285, 665-679	68
389	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. 2018 , 67, 931-944	87
388	Lung cancer epigenetics: From knowledge to applications. 2018 , 51, 116-128	142
387	Early Phase Cancer Immunotherapy. 2018 ,	1
386	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. 2018 , 243-280	
385	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. 2018 , 67, 381-392	73
384	Nanoparticle Formulation improves doxorubicin efficacy by enhancing host antitumor immunity. 2018 , 269, 364-373	36
383	Breast Cancer Immunotherapy: Facts and Hopes. 2018 , 24, 511-520	271
382	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. 2018 , 20, 145	11
381	Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system. 2018 , 124, 4597-4600	4
380	PI3K β inhibition promotes anti-tumor immunity through direct enhancement of effector CD8 T-cell activity. 2018 , 6, 158	39
379	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. 2018 , 9, 1443	11
378	Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. 2018 , 10, 86	9

377	Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. 2018 , 9, 1977	78
376	The role of endothelial colony forming cells in kidney cancer pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. 2018 , 132, 89-99	22
375	Degradation-Regulatable Architected Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy. 2018 , 28, 1804490	27
374	Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. 2018 , 9, 2250	24
373	Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. 2018 , 13, e0204490	15
372	Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. 2018 , 204, 47-54	8
371	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. 2018 , 6, 1561-1577	85
370	Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. 2018 , 6, 88	28
369	Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management. 2018 , 19,	7
368	Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity. 2018 , 138, 1-39	1
367	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. 2018 , 7, e1466018	32
366	Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4 and CD8 T-cell Interplay. 2018 , 78, 4943-4956	22
365	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. 2018 , 17, 258-273	29
364	A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells. 2018 , 8, 31-44	36
363	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. 2018 , 9, 398	274
362	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. 2018 , 9, 1310	260
361	Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. 2018 , 6, 54	20
360	Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. 2018 , 37, 5952-5966	44

359	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. 2018 , 19,	50
358	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. 2018 , 8, 92	356
357	Epigenetic mechanisms of tumor resistance to immunotherapy. 2018 , 75, 4163-4176	21
356	Myeloid-derived suppressor cells and their role in gynecological malignancies. 2018 , 40, 1010428318776485	16
355	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. 2019 , 29, 31-43	54
354	Nuclear Receptors: Recent Drug Discovery for Cancer Therapies. 2019 , 40, 1207-1249	29
353	Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. 2019 , 60, 3350-3362	1
352	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial. 2019 , 5, 1464-1472	18
351	Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy. 2019 , 144, 3-15	29
350	Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. 2019 , 7, 1497-1510	33
349	Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy. 2019 , 79, 4149-4159	28
348	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. 2019 , 10, 1337	63
347	Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model. 2019 , 37, 7256-7268	9
346	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. 2019 , 5, 34	32
345	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. 2019 , 122, 22-41	1
344	VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. 2019 , 42, 101308	45
343	If we build it they will come: targeting the immune response to breast cancer. 2019 , 5, 37	76
342	Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). 2019 , 7, 294	26

341	Neutrophil Maturity in Cancer. 2019 , 10, 1912	44
340	Improving cancer immunotherapy through nanotechnology. 2019 , 19, 587-602	257
339	Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance. 2019 , 11, 1263-1266	1
338	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. 2019 , 45, 225-240	5
337	Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer. 2019 , 9, 855	31
336	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. 2019 , 12, 119-132	22
335	Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases. 2019 , 13, 24-31	2
334	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. 2019 , 9, 546-563	123
333	Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. 2019 , 6, 1802281	26
332	High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity. 2019 , 44, 112-125	58
331	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. 2019 , 11,	55
330	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. 2019 , 10, 1015	22
329	Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer. 2019 , 18, 96	12
328	Current Status of Immunotherapies for Treating Pancreatic Cancer. 2019 , 21, 60	24
327	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. 2019 , 25, 4644-4655	41
326	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. 2019 , 19, 415	33
325	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. 2019 , 7, 1064-1078	69
324	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248

323	Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. 2019 , 10, 771	94
322	Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. 2019 , 21, 37	50
321	Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF- α -PD-L1 pathway. 2019 , 7, 54	54
320	Myeloid-Derived Suppressor Cells in Sepsis. 2019 , 10, 327	79
319	Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. 2019 , 11,	35
318	Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy. 2019 , 19, 547-560	6
317	Prostaglandin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets. 2019 , 10, 475	38
316	Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. 2019 , 10, 8	87
315	Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle". 2019 , 23, 70-85	19
314	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. 2019 , 9, 8332-8343	17
313	Histone deacetylase inhibition promotes intratumoral CD8 T-cell responses, sensitizing murine breast tumors to anti-PD1. 2019 , 68, 2081-2094	12
312	Visualization and quantification of homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. 2019 , 9, 5869-5885	19
311	DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses. 2019 , 12, 10903-10916	23
310	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. 2019 , 25, 6623-6632	59
309	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. 2019 , 11, 188	8
308	Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. 2019 , 36, 47-63	19
307	Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. 2019 , 2, 18-18	3
306	Immunological Effects of Epigenetic Modifiers. 2019 , 11,	10

305	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. 2019 , 77-101	
304	Overcoming Endocrine Resistance in Breast Cancer: mTOR Inhibitors and New Drugs. 2019 , 393-422	2
303	T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. 2019 , 21, 341-357	8
302	Cancer Epigenomics on Precision Medicine and Immunotherapy. 2019 , 483-503	
301	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. 2019 , 68, 379-393	58
300	Checkpoints and beyond - Immunotherapy in colorectal cancer. 2019 , 55, 78-89	21
299	The emerging role of epigenetic therapeutics in immuno-oncology. 2020 , 17, 75-90	116
298	The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment. 2020 , 60, 138-147	13
297	Biomarker-guided therapy for colorectal cancer: strength in complexity. 2020 , 17, 11-32	103
296	Immune checkpoints in the tumor microenvironment. 2020 , 65, 1-12	62
295	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. 2020 , 26, 704-716	12
294	Combining epigenetic and immune therapy to overcome cancer resistance. 2020 , 65, 99-113	35
293	Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. 2020 , 10, 270-287	68
292	Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN- γ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model. 2019 , 21,	12
291	Epigenetics of colorectal cancer: biomarker and therapeutic potential. 2020 , 17, 111-130	191
290	m A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. 2020 , 39, e104514	89
289	Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer. 2020 , 89, 107077	8
288	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. 2020 , 21,	4

287	The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. 2020 , 8, 576946	44
286	An update on colorectal cancer microenvironment, epigenetic and immunotherapy. 2020 , 89, 107041	8
285	Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy. 2020 , 32, 107848	40
284	Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy. 2020 , 50, 1871-1884	4
283	Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. 2020 , 18, 360	58
282	Emerging treatment options for patients with high-risk myelodysplastic syndrome. 2020 , 11, 2040620720955086	
281	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. 2020 , 11, 578877	24
280	Antifade Carbon Dots on a Plasmonic Substrate for Enhanced Protein Detection in Immunotherapy. 2020 , 5, 4027-4034	4
279	Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors. 2020 , 11, 5696	32
278	Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. 2020 , 588, 693-698	72
277	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. 2020 , 8,	12
276	Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas. 2020 , 10, 13343	10
275	Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough. 2020 , 258, 118128	8
274	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. 2020 , 10, 1195	24
273	DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. 2020 , 21, 182	13
272	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. 2020 , 11, 1680	72
271	Image-Guided Interventions in Oncology. 2020 ,	
270	ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 20159-20170	11.5 123

269	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 2020 , 126, 4485-4497	12
268	Targeting the immune milieu in gastrointestinal cancers. 2020 , 55, 909-926	2
267	Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy. 2020 , 23, 101458	8
266	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. 2020 , 21, 263	7
265	Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. 2020 , 217,	6
264	Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. 2020 , 9, 8086-8121	34
263	Bone morphogenetic protein 7 promotes resistance to immunotherapy. 2020 , 11, 4840	12
262	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. 2020 , 5, 141	13
261	Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. 2020 , 12,	14
260	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. 2020 , 19, 141	45
259	Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists. 2020 , 12,	7
258	Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology.. 2020 , 4,	0
257	Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. 2020 , 8, 582370	23
256	Small molecules-Giant leaps for immuno-oncology. 2020 , 59, 1-62	0
255	Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. 2020 , 6, eaax7881	66
254	LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. 2020 , 31, 863-880	8
253	Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. 2020 , 11, 783	43
252	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. 2020 , 20, 523	11

251	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. 2020 , 11, 1469	21
250	Impact of epigenetic modifiers on the immune system. 2020 , 315-352	
249	Oligometastatic Disease and Interventional Oncology: Rationale and Research Directions. 2020 , 26, 166-173	1
248	Regulation of Cancer Immune Checkpoints. 2020 ,	2
247	Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. 2020 , 9, 1734268	15
246	HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. 2020 , 11, 472-482	22
245	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. 2020 , 8, 141	17
244	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. 2020 , 9,	121
243	Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer. 2020 , 10, 992	20
242	Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. 2020 , 69, 2169-2178	3
241	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. 2020 , 579, 284-290	109
240	High-dose vitamin C enhances cancer immunotherapy. 2020 , 12,	65
239	5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. 2020 , 122, 1194-1204	7
238	Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models. 2020 , 108, 81-92	12
237	Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. 2020 , 12,	104
236	Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle. 2020 , 13, 83-94	16
235	The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020 , 10,	13
234	Rational targeting of immunosuppressive neutrophils in cancer. 2020 , 212, 107556	9

233	Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. 2020 , 11, 814	39
232	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. 2020 , 52, 856-871.e8	154
231	Lifting the innate immune barriers to antitumor immunity. 2020 , 8,	24
230	Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. 2020 , 10, 699	14
229	Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention. 2020 , 59, 852-861	4
228	CytoMAP: A Spatial Analysis Toolbox Reveals Features of Myeloid Cell Organization in Lymphoid Tissues. 2020 , 31, 107523	60
227	The unique immune microenvironment of liver metastases: Challenges and opportunities. 2021 , 71, 143-156	7
226	Myeloid-derived suppressor cells and regulatory T cells share common immunoregulatory pathways-related microRNAs that are dysregulated by acute lymphoblastic leukemia and chemotherapy. 2021 , 82, 36-45	2
225	Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. 2021 , 12, 145-152	6
224	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. 2021 , 27, 1019-1028	14
223	Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. 2021 , 14, 100949	1
222	Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer. 2021 , 5, 17-38	5
221	CaCO-Assisted Preparation of pH-Responsive Immune-Modulating Nanoparticles for Augmented Chemo-Immunotherapy. 2020 , 13, 29	15
220	Brief review on the roles of neutrophils in cancer development. 2021 , 109, 407-413	4
219	Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells. 2021 , 13,	6
218	Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. 2020 , 10, 614468	12
217	Non-depleting reformation of immunosuppressive myeloid cells to broaden the application of anti-PD therapy. 2021 , 13, 4420-4431	9
216	Reduced CD5 on CD8 T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. 2020 , 11, 584937	0

215	Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity.	0
214	Colon cancer and immunotherapy-can we go beyond microsatellite instability?. 2021 , 6, 12	10
213	The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity. 2020 , 11, 594540	2
212	The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy. 2021 , 85-102	
211	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. 2021 , 13,	25
210	Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer. 2021 , 9, 454-469	5
209	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in uveal melanoma.	1
208	A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 T Cell Epitopes. 2021 , 15, 4357-4371	15
207	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. 2021 , 40, 74	2
206	Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer. 2021 , 269, 120666	8
205	Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. 2021 , 9,	13
204	Inhibition of PI3K Isoform p110 α Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. 2021 , 13,	2
203	Cu/Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer. 2021 , 64, 2705-2713	1
202	Parthanatos-inducing zinc agent C010DS-Zn elicits anti-tumor immune responses involving T cells and macrophages in vivo.	
201	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. 2021 , 9, 641469	30
200	Inspired Epigenetic Modulation Synergy with Adenosine Inhibition Elicits Pyroptosis and Potentiates Cancer Immunotherapy. 2021 , 31, 2100007	12
199	Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. 2021 , 13, 63	8
198	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. 2021 , 12, 652160	5

197	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. 2021 , 11, 6956	0
196	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. 2021 , 27, 3757-3771	5
195	Development of Immunotherapy Combination Strategies in Cancer. 2021 , 11, 1368-1397	27
194	Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. 2021 , 13,	3
193	Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. 2021 , 35, 108948	6
192	Long Noncoding RNA RUNXOR Promotes Myeloid-Derived Suppressor Cell Expansion and Functions via Enhancing Immunosuppressive Molecule Expressions during Latent HIV Infection. 2021 , 206, 2052-2060	3
191	Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. 2021 , 10,	3
190	Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer. 2021 , 12, 484	1
189	Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers. 2021 , 13,	2
188	Leveraging epigenetics to enhance the efficacy of immunotherapy. 2021 , 13, 115	6
187	Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. 2021 , 40, 174	7
186	Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. 2021 , 35, 1873-1889	27
185	Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. 2021 , 10,	7
184	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). 2021 , 27, 5828-5837	5
183	Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy. 2022 , 15, 593	1
182	Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. 2021 , 13,	7
181	Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. 2021 , 13,	1
180	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. 2021 , 131,	7

179	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. 2021 , 131,	0
178	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. 2021 , 12, 5155	16
177	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. 2021 , 12, 5138	11
176	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. 2021 , 12, 5151	5
175	Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. 2021 , 17, 4583-4606	1
174	The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. 2021 , 21, 969	5
173	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. 2021 ,	3
172	Simultaneous targeting of TGF- β /PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. 2021 , 39, 1388-1403.e10	16
171	In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. 2021 , 184, 5357-5374.e22	15
170	Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. 2021 , 14, 147	7
169	A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target. 2021 , 1	0
168	Repurposing Radiation Therapy for Immuno-oncology. 2021 , 33, 683-693	1
167	Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. 2021 , 11,	1
166	Combined targeted therapy and immunotherapy for cancer treatment. 2021 , 9, 7643-7652	0
165	Epigenetic mechanisms of liver tumor resistance to immunotherapy. 2021 , 13, 979-1002	1
164	Development of D-melittin polymeric nanoparticles for anti-cancer treatment. 2021 , 277, 121076	7
163	Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. 2021 , 139, 65-75	1
162	Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies. 2021 , 173, 105702	3

161	Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer. 2022 , 409-435	1
160	Targeting tumor-associated neutrophils in immunotherapy. 2022 , 147-161	0
159	Upcoming immunotherapeutic combinations for B-cell lymphoma. 2021 , 1,	0
158	Immune Therapy: What Can We Learn From Acquired Resistance?. 2021 , 75-114	
157	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. 2021 , 10, 709-717	7
156	Small Molecular Immune Modulators as Anticancer Agents. 2020 , 1248, 547-618	1
155	Mechanisms of Resistance to Checkpoint Blockade Therapy. 2020 , 1248, 83-117	15
154	Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells. 2020 , 52, 729-731	10
153	Tweaking the DNA of myeloid cells curbs cancer spread. 2020 , 579, 196-197	2
152	Chromatin dependencies in cancer and inflammation. 2018 , 19, 245-261	36
151	p110PI3K as a therapeutic target of solid tumours. 2020 , 134, 1377-1397	7
150	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. 2021 , 11, 1212-1227	29
149	Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. 2020 , 130, 3865-3884	79
148	Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. 2017 , 127, 3039-3051	87
147	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. 2019 , 129, 1278-1294	62
146	Addressing intra-tumoral heterogeneity and therapy resistance. 2016 , 7, 72322-72342	49
145	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. 2016 , 7, 68278-68291	38
144	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. 2017 , 8, 21177-21186	19

143	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. 2017 , 8, 44159-44170	22
142	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. 2017 , 8, 86969-86984	3
141	Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck. 2017 , 8, 112797-112808	4
140	Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. 2019 , 10, 1458-1472	10
139	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. 2016 , 7, 7390-402	59
138	Immune Checkpoint Inhibitors: Basics and Challenges. 2019 , 26, 3009-3025	102
137	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. 2020 , 27, 2402-2448	6
136	Immune Checkpoint Inhibitors in AML-A New Frontier. 2020 , 20, 545-557	1
135	[Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy]. 2021 , 24, 112-123	1
134	Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer. 2021 , 21, 149	7
133	Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells. 2020 , 28, 1-17	1
132	Therapeutic strategies to reverse immunosuppressive breast cancer microenvironment. 2016 , 4, 1	2
131	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. 2021 , 10,	2
130	Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha.	
129	Cancer Epigenomics on Precision Medicine and Immunotherapy. 2017 , 1-21	
128	Neutrophil counts and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.	
127	Panorama epigenético del mesotelioma pleural maligno. 2019 , 78, 395-403	
126	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. 2019 , 1-24	

125	Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages.		
124	CytoMAP: a spatial analysis toolbox reveals features of myeloid cell organization in lymphoid tissues.		1
123	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. 2020 , 1141-1164		
122	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. 2020 , 3, 3-15		2
121	A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. 2021 , 24, 103349		
120	Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
119	Immune Modulation in Interventional Oncology. 2020 , 371-387		
118	In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target.		
117	In vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target.		
116	Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. 2021 , 1		0
115	TGF- β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. 2021 , 1		2
114	Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas. 2020 , 12, 1149-1152		
113	Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. 2017 , 7, 2032-2040		7
112	Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model. 2019 , 9, 529-545		14
111	Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. 2021 , 9,		6
110	Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I. 2021 ,		0
109	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. 2021 , 13,		0
108	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. 2021 ,		1

107	Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. 2021,	2
106	Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.. 2021, 12, 782852	2
105	Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.. 2021, 280, 121312	3
104	Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.. 2022, 14, 3	1
103	Immuno-oncology trends: preclinical models, biomarkers, and clinical development.. 2022, 10,	0
102	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.. 2022, 21, 28	22
101	Induction of Immunogenic Cell Death by Photodynamic Therapy Mediated by Aluminum-Phthalocyanine in Nanoemulsion.. 2022, 14,	1
100	Nanozyme-Based Enhanced Cancer Immunotherapy.. 2022, 1	4
99	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.. 2022, 13, 809761	5
98	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.. 2022, 13, 781660	2
97	Light-Triggered Efficient Sequential Drug Delivery of Biomimetic Nanosystem for Multimodal Chemo-, Antiangiogenic, and Anti-MDSC Therapy in Melanoma.. 2022, e2106682	11
96	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.. 2022, 14,	0
95	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.. 2022, 108114	2
94	Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies.. 2022, 170, 103592	0
93	Immunotherapy resistance of lung cancer.. 2022, 5, 114-128	
92	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.. 2022, 12,	3
91	Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches.. 2022, 8, eabj1262	1
90	Combinatorial immunotherapy strategies for cancer vaccines. 2022, 137-154	

89	Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation.	
88	Tumor-derived Jagged1 promotes cancer progression through immune evasion.. 2022 , 38, 110492	1
87	Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment.. 2022 ,	1
86	Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.. 2022 , 12, 841977	1
85	PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.. 2022 , 38, 110582	3
84	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.. 2022 , 23,	0
83	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.. 2022 , 233, 114228	0
82	Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity.. 2022 , 101753	1
81	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.. 2022 , 20, 101405	0
80	The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.. 2021 , 23,	1
79	Development of Small-Molecule STING Activators for Cancer Immunotherapy.. 2021 , 10,	1
78	Impact of cancer cell-intrinsic features on neutrophil behavior. 2021 , 101546	2
77	Data_Sheet_1.PDF. 2019 ,	
76	Data_Sheet_1.PDF. 2020 ,	
75	Data_Sheet_1.zip. 2020 ,	
74	Table_1.XLSX. 2019 ,	
73	Data_Sheet_1.docx. 2020 ,	
72	Data_Sheet_1.docx. 2018 ,	

71 Data_Sheet_1.PDF. 2020,

70 Image_1.tiff. 2020,

69 Image_1.PNG. 2020,

68 Image_2.TIF. 2020,

67 Image_3.TIFF. 2020,

66 Image_4.TIF. 2020,

65 Image_5.TIFF. 2020,

64 Image_6.PNG. 2020,

63 Image_7.PNG. 2020,

62 Image_8.TIFF. 2020,

61 Table_1.XLSX. 2020,

60 Table_10.XLSX. 2020,

59 Table_11.XLSX. 2020,

58 Table_2.XLSX. 2020,

57 Table_3.XLSX. 2020,

56 Table_4.XLSX. 2020,

55 Table_5.XLSX. 2020,

54 Table_6.XLSX. 2020,

53 Table_7.XLSX. 2020,

52 Table_8.XLSX. 2020,

51 Table_9.XLSX. 2020,

50 Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy.. 2022, 11, 22 1

49 PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. 2022, 23, 5837 0

48 Induction of M-MDSCs with IL6/GM-CSF from adherence monocytes and inhibition by WP1066. 2022, 24,

47 Cancer-associated fibroblasts suppress CD8+ T cell infiltration and confer resistance to immune checkpoint blockade. 2

46 Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. 9

45 Epigenomics in Malignant Pleural Mesothelioma.

44 3,3'-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells. 2022, 17, 0

43 Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma. 2022, 22, 0

42 A pan-tumor-siRNA aptamer chimera to block Nonsense-Mediated mRNA Decay (NMD) inflames and suppresses tumor progression. 2022, 2

41 The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. 2022, 23, 8141 1

40 Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. 2022, 40, 111256 1

39 Immune cellular components and signaling pathways in the tumor microenvironment. 2022, 1

38 The emerging roles of HDACs and their therapeutic implications in cancer. 2022, 931, 175216 2

37 Blockade of IL-6 inhibits tumor immune evasion and improves antiPD-1 immunotherapy. 2022, 158, 155976 0

36 Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. 2022, 14, 4669 0

35	Clinical Applications of Histone Deacetylase Inhibitors. 2023 , 793-819	0
34	Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. 2022 , 21,	5
33	Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche. 12,	1
32	Neutrophils and neutrophil extracellular traps in cancer: promising targets for engineered nanomaterials.	1
31	Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity. 2022 , 290, 121841	1
30	Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in mice via multichannel image segmentation.	0
29	AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model. 2022 , 27, 6721	0
28	Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1.	0
27	C/EBP β enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification.	1
26	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. 2022 , 11,	2
25	VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance.	1
24	Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression. 2023 , 108, 154508	0
23	Epigenetic modifications in the accumulation and function of myeloid-derived suppressor cells. 13,	0
22	Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. 12,	0
21	PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?. 2022 , 103435	1
20	Immune checkpoint inhibitor resistance in hepatocellular carcinoma. 2023 , 555, 216038	0
19	Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models. 2022 , 14, 2796	0
18	Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.	0

17	Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. 2022 , 132,	0
16	Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance. 2022 , 14, 6208	1
15	Role of PCIF1 -mediated 5?-cap N6 -methyladeonsine mRNA methylation in colorectal cancer and anti-PD -1 immunotherapy.	0
14	N1 versus N2 and PMN-MDSC: A critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology.	0
13	Epigenetics in Cancer Biology. 2022 ,	0
12	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. 2023 , 15, 175883592211383	1
11	Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer. 2023 , 18, e0279063	0
10	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. 2023 , 30,	1
9	Mechanisms driving the immunoregulatory function of cancer cells.	2
8	Novel Combination Therapy for Triple-Negative Breast Cancer based on an Intelligent Hollow Carbon Sphere. 2023 , 6,	0
7	Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer. OF1-OF14	0
6	Discovery of Targets for ImmuneMetabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha. 2023 , 13, 672-701	0
5	NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models. 2023 , 15, 1468	0
4	Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. 2023 , 129, 1319-1350	0
3	Characterization of immune cell populations in syngeneic murine tumor models.	0
2	Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. 14,	0
1	An Endogenous Retrovirus Vaccine Encoding an Envelope with a Mutated Immunosuppressive Domain in Combination with Anti-PD1 Treatment Eradicates Established Tumours in Mice. 2023 , 15, 926	0